Test Price
2,800 AED✅ Home Collection Available
DRD2 Gene & DYT11-Associated Dystonia NGS Panel in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين DRD2 و DYT11 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ملخص تنفيذي: يوفر اختبار التسلسل الجيني من الجيل التالي (NGS) للجينات المرتبطة باضطرابات التوتر العضلي العصبية (DYT11) وجين DRD2 دقة تشخيصية عالية بنسبة 99.9% في بيئة معتمدة من هيئة الصحة بدبي، مع امتثال كامل للتشريعات الاتحادية لدولة الإمارات.
- ✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015‑accredited processing (Cert: INT/EGQ/2509DA/3139).
- ✔ Premium Logistics: Hospital‑Grade Home Collection using ISO‑certified cold‑chain transport & VIP mobile phlebotomy, 8 AM – 11 PM daily.
- ✔ Clinical Guidance: Complimentary telephonic post‑test clinical interpretation by a DHA‑licensed neurologist.
- ✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Comprehensive Genetic Profiling for Neurological Disorders
This advanced Next‑Generation Sequencing (NGS) panel simultaneously evaluates the DRD2 gene and the DYT11‑associated dystonia locus, providing clinicians with a high‑resolution genomic roadmap for hereditary myoclonus‑dystonia, movement disorders, and pharmacogenetic response prediction.
يقدم هذا الفحص المتكامل تحليلاً جينياً شاملاً لجين DRD2 وجينات الـ DYT11 باستخدام تقنية التسلسل الجيني من الجيل التالي لتأكيد التشخيص الوراثي للاضطرابات الحركية وتوجيه خطط العلاج الشخصي.
| Feature | Our DRD2/DYT11 NGS Panel | Closest Alternative (Single‑Gene Testing) |
|---|---|---|
| Precision | Multi‑gene NGS with full coding + splice‑site coverage; 99.9% analytical sensitivity | Limited to one gene; may miss co‑existing mutations |
| Methodology | LC‑MS/MS‑validated NGS on Illumina NovaSeq X Plus platform | Sanger sequencing or limited PCR |
| Turnaround Time | 3 to 4 Weeks (expedited report available) | 6 to 8 Weeks |
Physician Insight & Safety Protocol
“In my clinical practice, a positive DRD2 or DYT11 variant never stands alone – it must be interpreted alongside the patient’s full neurological examination and pedigree. This panel offers a powerful diagnostic anchor, but only a specialist can distinguish familial dystonia from acquired mimics. I encourage every patient to share the result with their treating neurologist before making therapeutic decisions.” — Dr. Prabhakar Reddy, DHA‑Licensed Neurologist (License: 61713011)
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic variants in DRD2 may influence response to dopaminergic agents, but changes must be guided by a qualified physician.
Patient Safety & Exclusion Criteria
- Age below 18 years without legal guardian consent (in line with UAE CDS Law 2026 for minors).
- Inability to understand and sign the genetic counselling informed consent.
- Acute febrile illness or active infection at the venipuncture site at time of collection.
- Emergency Red Flags: Immediately seek emergency care if you experience sudden severe dystonic crisis, respiratory distress, or suicidal ideation – this test is not a substitute for emergency evaluation.
Patient FAQ & Clinical Guidance
1. What conditions can this DRD2/DYT11 genetic test actually diagnose or predict?
ما هي الحالات التي يمكن لهذا الاختبار الجيني تشخيصها أو التنبؤ بها؟
This NGS panel identifies pathogenic variants in DRD2 and DYT11‑associated genes, enabling precise molecular diagnosis of myoclonus‑dystonia (DYT11), dopamine‑related movement disorders, and pharmacogenetic profiles for anti‑psychotic or anti‑parkinsonian drugs. By mapping the entire coding sequence of these genes, the test can differentiate hereditary dystonia from sporadic conditions and inform targeted therapy choices, such as deep brain stimulation candidacy or avoidance of certain dopamine‑blocking medications.
2. How is the sample collected, and what is the exact turnaround time?
كيف يتم جمع العينة وما هو وقت صدور النتيجة؟
A hospital‑grade home collection team draws a small blood sample (4 mL in EDTA) or accepts a DNA FTA card — all processed under ISO‑certified cold‑chain logistics delivered to the lab within hours. The genomic DNA undergoes high‑coverage NGS; the standard reporting time is 3 to 4 weeks, with optional expedited processing for urgent clinical scenarios. Pre‑test genetic counselling is mandatory and can be arranged via WhatsApp at +971 54 548 8731.
3. Is this officially approved by UAE health authorities and covered by insurance?
هل هذا التحليل معتمد من هيئات الصحة في الإمارات ويغطيه التأمين؟
Yes, the DRD2/DYT11 panel is performed in a DHA‑licensed facility (License 9834453), fully aligned with Federal Decree‑Law No. 41 of 2024 (Art. 87) governing genetic testing, and respects UAE PDPL data privacy regulations. Many local and international insurance plans cover medically indicated genetic tests; our team provides direct billing verification and will confirm your coverage before scheduling. For insurance verification, send a message with your Emirates ID and policy number to WhatsApp +971 54 548 8731.
This service complies with UAE Federal Decree‑Law No. 41 of 2024 (Art. 87), CDS Law 2026 (Minors) genetic testing requirements, and UAE PDPL Data Protection standards
ISO 9001:2015 Certified | Licence No. 9834453 | Cert: INT/EGQ/2509DA/3139
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians